Home » Stocks » IRIDEX Corporation

IRIDEX Corporation (IRIX)

Stock Price: $2.09 USD 0.02 (0.97%)
Updated Aug 4, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 28.82M
Revenue (ttm) 41.87M
Net Income (ttm) -7.42M
Shares Out 13.79M
EPS (ttm) -0.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $2.09
Previous Close $2.07
Change ($) 0.02
Change (%) 0.97%
Day's Open 2.01
Day's Range 2.00 - 2.09
Day's Volume 17,779
52-Week Range 1.22 - 4.24

More Stats

Market Cap 28.82M
Enterprise Value 20.55M
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 13.79M
Float 10.24M
EPS (basic) -0.54
EPS (diluted) -0.54
FCF / Share -0.41
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 163,982
Short Ratio 8.35
Short % of Float 1.18%
Beta 1.13
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 0.69
PB Ratio 1.32
Revenue 41.87M
Operating Income -7.59M
Net Income -7.42M
Free Cash Flow -5.70M
Net Cash 8.27M
Net Cash / Share 0.60
Gross Margin 42.84%
Operating Margin -18.13%
Profit Margin -17.70%
FCF Margin -13.61%
ROA -13.26%
ROE -30.52%
ROIC -47.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$4.75*
(127.27% upside)
Low
4.00
Current: $2.09
High
5.50
Target: 4.75
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue43.4542.6041.5946.1641.7642.8138.2733.8633.1632.31
Revenue Growth1.99%2.42%-9.89%10.54%-2.47%11.86%13.04%2.11%2.63%-
Gross Profit17.9417.4715.5020.8419.9521.4118.5916.3516.2916.20
Operating Income-8.97-12.87-12.89-2.570.292.592.63-0.062.731.99
Net Income-8.81-12.81-12.87-11.710.4710.042.231.442.613.05
Shares Outstanding13.7112.2011.5610.179.969.899.258.9410.2310.13
Earnings Per Share-0.64-1.05-1.11-1.150.050.970.220.160.260.30
EPS Growth-----94.85%340.91%37.5%-38.46%-13.33%-
Operating Cash Flow-7.91-10.03-3.57-0.14-0.594.010.77-1.142.251.14
Capital Expenditures-0.13-0.44-0.40-1.06-0.88-0.57-0.38-0.39-0.20-0.19
Free Cash Flow-8.04-10.47-3.97-1.21-1.473.450.39-1.532.050.94
Cash & Equivalents12.6521.1921.7123.7510.0013.3013.4411.9010.798.35
Total Debt3.21---------
Net Cash / Debt9.4421.1921.7123.7510.0013.3013.4411.9010.798.35
Assets34.8141.6741.6548.1441.8241.8233.6828.9132.1529.22
Liabilities12.1111.7111.128.988.148.087.827.019.729.79
Book Value22.7129.9630.5239.1633.6933.7425.8521.9122.4319.43
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name IRIDEX Corporation
Country United States
Employees 94
CEO David I. Bruce

Stock Information

Ticker Symbol IRIX
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Unique Identifier NASDAQ: IRIX
IPO Date February 15, 1996

Description

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. It also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, the company offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system that delivers laser to treat glaucoma; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. It serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. IRIDEX Corporation markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was founded in 1989 and is headquartered in Mountain View, California.